TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…

TS-062822 — Humanized Antibody-drugs conjugate for chemo-immunotherapy of multiple cancer types

TS-062421 — The Need: Addressing the Global HTLV-1 Epidemic with a Novel Vaccine Human T cell leukemia virus type-1 (HTLV-1) is a significant global health concern, responsible for causing Adult T cell leukemia/lymphoma (ATLL) and human myelopathy/tropical spastic paraparesis (HAM/TSP). With over 10 million pe…

TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…

TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…

TS-037741 — The SMN2 gene contains sequences that regulate the level of inclusion of SMN exon7 in SMN mRNA, and some of these act in a negative manner. Antisense oligonucleotides to block the negative regulating protein binding to these sites can increase inclusion of SMN exon 7 and thus, the amount of SMN being produced.

TS-037675 — Novel method of using live attenuated vaccines to prevent infection of hMVP.

TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.